Vesalius Biocapital III Announces Final Close of EUR 120 million Fund

Life sciences focused fund has executed three investments to date

Luxembourg-Strassen, June 25, 2019 – Vesalius Biocapital III (‘Vesalius’), the specialist life sciences venture capital investor, announces the final close of the VBC III fund securing EUR 120 million of equity commitments. This includes commitments of EUR 30 million from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. The fund is a validation of Vesalius’ proven approach to invest in later-stage European life sciences companies, providing capital to support their development. Vesalius Biocapital III has executed three investments to date.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH